Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,577 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Among authors: zhu b. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147 Clinical Trial.
Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions.
Elliott C, Arnold DL, Chen H, Ke C, Zhu L, Chang I, Cahir-McFarland E, Fisher E, Zhu B, Gheuens S, Scaramozza M, Beynon V, Franchimont N, Bradley DP, Belachew S. Elliott C, et al. Among authors: zhu b, zhu l. AJNR Am J Neuroradiol. 2020 Sep;41(9):1584-1591. doi: 10.3174/ajnr.A6742. Epub 2020 Aug 20. AJNR Am J Neuroradiol. 2020. PMID: 32819894 Free PMC article. Clinical Trial.
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise.
Elliott C, Momayyezsiahkal P, Arnold DL, Liu D, Ke J, Zhu L, Zhu B, George IC, Bradley DP, Fisher E, Cahir-McFarland E, Stys PK, Geurts JJG, Franchimont N, Gafson A, Belachew S. Elliott C, et al. Among authors: zhu b, zhu l. Brain Commun. 2021 Aug 10;3(3):fcab176. doi: 10.1093/braincomms/fcab176. eCollection 2021. Brain Commun. 2021. PMID: 34557664 Free PMC article.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, Zhu B. Chang I, et al. Among authors: zhu b. Mult Scler. 2022 Dec;28(14):2263-2273. doi: 10.1177/13524585221114997. Epub 2022 Sep 21. Mult Scler. 2022. PMID: 36131595 Free PMC article. Clinical Trial.
Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis.
Jiang X, Shen C, Caba B, Arnold DL, Elliott C, Zhu B, Fisher E, Belachew S, Gafson AR. Jiang X, et al. Among authors: zhu b. Mult Scler Relat Disord. 2023 Sep;77:104869. doi: 10.1016/j.msard.2023.104869. Epub 2023 Jul 2. Mult Scler Relat Disord. 2023. PMID: 37459715 Free article.
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR, Kamath A, Button J, Kamath V, Mendoza JP, Zhu B, Plavina T, Woodward C, Penner N. Edwards KR, et al. Among authors: zhu b. Mult Scler Relat Disord. 2021 Jun;51:102861. doi: 10.1016/j.msard.2021.102861. Epub 2021 Feb 24. Mult Scler Relat Disord. 2021. PMID: 33773271
10,577 results
You have reached the last available page of results. Please see the User Guide for more information.